Synlogic Inc · OTC:SYBX
Synlogic — FY2021 Earnings Presentation
22 slides from Synlogic's earnings presentation, Mar 17, 2022
Slide 1: Q4 and Full Year 2021 Financial Results & Business Update
Transforming Medicine through Synthetic Biology Q4 and Full Year 2021 Financial Results & Business Update March 17, 2022 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: Opening Remarks
© 2020 SYNLOGIC. QU©AR2T0E1R9LYSYRNELSOUGLTICS.. AALLLL RRIIGGHHTTSS RREESSEERRVVEEDD.. || 33 Opening Remarks Dr. Aoife Brennan MB CHB President & CEO
Slide 4: Multiple Anticipated Milestones as PKU Program Approaches Phase 3
PKU Proof of concept from Phase 2 interim analysis with lead candidate PKU Next generation candidate showed greater potency HCU 2nd rare metabolic disease drug candidate entered pre-IND studies HOX Achieved proof of mechanism in healthy volunteers IBD Established Roche collaboration, achieved first
Slide 5: Synthetic Biotics: A New Paradigm of Biotherapeutics
Synthetic Biotics: A New Paradigm of Biotherapeutics GI = gastrointestinal Well-characterized probiotic chassis Programable, precision genetic engineering + Targets validated biology in metabolic and immunological diseases Safe chassis, with >100 years of human experience Orally-administered conveni
Slide 6: PKU: Unique Opportunity for Value Creation
PKU: Unique Opportunity for Value Creation PKU = phenylketonuria Significant unmet medical need - 75% of patients remain untreated De-risked path to registration Well-connected patient population at concentrated sites of care Differentiated profile established in POC Phase 3 initiation in H2 2022 ex
Slide 7: PKU Opportunity
© 2020 SYNLOGIC. QU©AR2T0E1R9LYSYRNELSOUGLTICS.. AALLLL RRIIGGHHTTSS RREESSEERRVVEEDD.. || 33 PKU Opportunity Molly Harper Chief Business Officer
Slide 8: Limitations of Current Options Create Need for a New Approach in PKU
*Responsive to BH4 (tetrahydrobiopterin) = molecule that the body produces to act as a cofactor with PAH, the enzyme that is impaired in PKU. Sapropterin is a synthetic form of BH4. NPKUA; 2. Patient numbers for sapropterin, pegvaliase derived from Biomarin financials and disclosures YE 2020; 3. Syn
Slide 9: Potentially Transformative Product Profile
Potentially Transformative Product Profile Efficacy Safety Oral administration Monotherapy or Adjunctive Use .Sources: Synlogic PKU Program Update, September 20, 20211, Synlogic Market Research 4Q 2021 Designed and Differentiated for PKU
Slide 10: PKU Clinical Development
© 2020 SYNLOGIC. QU©AR2T0E1R9LYSYRNELSOUGLTICS.. AALLLL RRIIGGHHTTSS RREESSEERRVVEEDD.. || 33 PKU Clinical Development Dr. Aoife Brennan MB CHB President & CEO
Slide 11: With POC Established, PKU Program Has Path to Phase 3
With POC Established, PKU Program Has Path to Phase 3 in 2022 September 2021 SYNB1618: POC established SYNB1934: Greater potency confirmed Phase 3: Committed based on strength of POC H1 2022* SYNB1618: Complete Phase 2 dataset SYNB1934: PKU patient data Monotherapy and adjunctive use data Phase 3 dr
Slide 12: Regulatory Path De-Risked at Multiple Levels
Regulatory Path De-Risked at Multiple Levels Disease Precedents in two FDA-approved drugs Platform Synthetic Biotics Drug Candidate SYNB1618/SYNB1934
Slide 13: Enteric Hyperoxaluria, Homocystinuria and Preclinical Programs
© 2020 SYNLOGIC. QU©AR2T0E1R9LYSYRNELSOUGLTICS.. AALLLL RRIIGGHHTTSS RREESSEERRVVEEDD.. || 33 Enteric Hyperoxaluria, Homocystinuria and Preclinical Programs Dave Hava, PhD Chief Scientific Officer
Slide 14: SYNB1353 for HCU: 2nd Rare Metabolic Disease Program
SYNB1353 for HCU: 2nd Rare Metabolic Disease Program Significant disease burden Builds on PKU success Strong synergies with PKU Gut lumen Methionine SYNB1353 Intestinal epithelium CBS = cystathionine beta-synthase 1. Development of an Investigational Methionine-consuming Synthetic Biotic Medicine (S
Slide 15: SYNB8802 for Enteric Hyperoxaluria: On Track for POC in 2022
SYNB8802 for Enteric Hyperoxaluria: On Track for POC in 2022 GI = gastrointestinal, CKD = chronic kidney disease, ESRD = end stage renal disease Acute Crises, Long-Term Damage Stomach Small Intestine Colon Consumes Oxalate Across GI Tract Dietary Oxalate SYNB8802
Slide 16: Platform's Progress Has Enabled Research Programs in New Areas
Platform’s Progress Has Enabled Research Programs in New Areas Immunological disease SYNB1618 Phe SYNB8802 Oxalate metabolism SYNB1934 Phe SYNB1353 Methionine Metabolic disease
Slide 17: Strength of Partners Reflects Platform Progress and Potential
Strength of Partners Reflects Platform Progress and Potential IND = Investigational New Drug
Slide 18: Financial Summary
© 2020 SYNLOGIC. QU©AR2T0E1R9LYSYRNELSOUGLTICS.. AALLLL RRIIGGHHTTSS RREESSEERRVVEEDD.. || 33 Financial Summary Michael Jensen Chief Financial Officer
Slide 19: Fourth Quarter and Year End 2021 Summary Results
Balance Sheet (unaudited) 31 December 2021 31 December 2020 Cash, Cash Equivalents, and Marketable Securities $136.6 M $100.4 M * weighted average shares used in computing net loss per shares - basic and diluted Fourth Quarter and Year End 2021 Summary Results Financial Performance (unaudited) 31 De
Slide 20: Concluding Remarks
© 2020 SYNLOGIC. QU©AR2TE1R9LYSYRNELSOUGLTICS.. AALLLL RRIIGGHHTTSS RREESSEERRVVEEDD.. || 1414 Concluding Remarks Dr. Aoife Brennan MB CHB President & CEO
Slide 21: Multiple Expected Near-Term Milestones
PKU Phase 2 data readout Æ H1 2022 PKU Phase 3 initiation Æ H2 2022 HCU Phase 1 data from healthy volunteers Æ H2 2022 Enteric hyperoxaluria proof of concept Æ 2022 Multiple Expected Near-Term Milestones Strong balance sheet: $136.6m* with projected runway into 2024 * As of December 31, 2021
Slide 22: Available For Questions
Available For Questions Dave Hava, PhD Chief Scientific Officer Michael Jensen Chief Financial Officer Aoife Brennan, MB ChB President & CEO Antoine Awad Chief Operating Officer Molly Harper Chief Business Officer